Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralymphatic grass and birch allergen immunotherapy for allergic rhinoconjunctivitis
2016-003369-24Phase 2Terminated
- Sponsor
- Allergy Centre
- Start
- Oct 2016
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of birch pollen extract and ALK Alutard 5-grasses in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Allergy Centre. Primary endpoint: Combined Symptom and Medication Score. Started Oct 2016; status: terminated.
02
Drugs
birch pollen extractALK Alutard 5-grasses
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2016-003369-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003369-24.